Fred Alger Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Fred Alger Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-407,170	Closed	-$41.5M	–	559
2023 Q2	$41.5M	Buy	407,170 +232,469	+133%	+$22M	0.21%	112
2023 Q1	$15.9M	Sell	174,701 -1,334,703	-88%	-$78.3M	0.09%	170
2022 Q4	$57.3M	Buy	1,509,404 +897,481	+147%	+$30.9M	0.31%	96
2022 Q3	$15.4M	Buy	+611,923	New	+$17M	0.08%	181
2021 Q1	–	Sell	-8,028	Closed	-$992K	–	520
2020 Q4	$992K	Sell	8,028 -181	-2%	-$23.8K	﹤0.01%	370
2020 Q3	$800K	Sell	8,209 -8,375	-51%	-$1.05M	﹤0.01%	360
2020 Q2	$2.59M	Buy	16,584 +2,842	+21%	+$432K	0.01%	293
2020 Q1	$1.98M	Buy	13,742 +5,242	+62%	+$1.01M	0.01%	273
2019 Q4	$1.74M	Buy	8,500 +5,500	+183%	+$1M	0.01%	298
2019 Q3	$241K	Buy	+3,000	New	+$255K	﹤0.01%	401
2019 Q1	–	Sell	-3,000	Closed	-$168K	–	577
2018 Q4	$168K	Buy	+3,000	New	+$183K	﹤0.01%	381

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fred Alger Management's RETA Position: Q3 2023 in Review

Fred Alger Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 407,170 shares — an estimated $41.5M sold.

Fred Alger Management first reported a position in RETA in Q4 2018 and held it in 11 quarters. The position peaked at $57.3M in Q4 2022. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Fred Alger Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Fred Alger Management sold 407,170 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $41.5M.
Fred Alger Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 11 quarters.
Fred Alger Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $57.3M in Q4 2022.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Fred Alger Management's 13F filing for Q3 2023, filed 14 Nov 2023.